MaxCyte, Inc.

At MaxCyte, a clinical-stage global cell-based therapies and life sciences company, we believe in the power of next-generation cell and gene therapies to revolutionize medical treatment and ultimately save lives. As the inventors of the premier cell engineering enabling platform, we help bring the promise of cell and gene-editing therapies to life. Our Flow Electroporation® technology and next-generation ExPERT® platform enable our partners to accelerate, streamline, and improve the drug development process from the early stages of research to commercialization. We have placed our technology with leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. In addition, MaxCyte licenses have been granted to more than 100 cell therapy programmes, with more than 70 licensed for clinical use. Learn more at www.maxcyte.com.